Skip to content

SKYRIZI (risankizumab) | Injection | AbbVie


What is STELARA?

Stelara is an immunosuppressant that reduces the effects of a chemical substance in the body that can cause inflammation.

Stelara is used to treat plaque psoriasis and psoriatic arthritis in adults and children who are at least 6 years old.

Stelara is used in adults to treat moderately to severely active Crohn’s disease after other medicines have been tried without success.

Stelara is also used in adults to treat moderately to severely active ulcerative colitis.


Skyrizi (risankizumab) is a medication used to treat adults with certain types of plaque psoriasis, psoriatic arthritis, and Crohn’s disease, which are all autoimmune disorders. Skyrizi works by targeting a specific protein in the immune system called interleukin-23 (IL-23), which is responsible for causing inflammation in these conditions. Skyrizi helps reduce inflammation, which improves the symptoms of these conditions, by attaching to and blocking IL-23.

Skyrizi is a monoclonal antibody that belongs to a class of medications called interleukin-23 antagonists. Skyrizi is given as a subcutaneous injection for plaque psoriasis and psoriatic arthritis, and for Crohn’s disease, it is given as an intravenous infusion for the induction period, then as a subcutaneous injection for maintenance dosing.

Skyrizi is FDA approved to treat:

  • Plaque Psoriasis moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
  • Psoriatic Arthritis active psoriatic arthritis in adults.
  • Crohn’s Disease moderately to severely active Crohn’s disease in adults.